title: Plasma t-PA and PAl-1 antigen concentrations in non-insulin dependent diabetic patients: effects of treatment modality on fibrinolysis.
abstract: Basal plasma tissue type plasminogen activator (t-PA) and plasminogen activator inhibitor type 1 (PAl-1) antigen levels were studied in 49 non-insulin dependent diabetic patients (23 men, 26 women: ages 51.3 +/- 14.9 years) and 16 age matched non-diabetic subjects (9 men, 7 women: ages 49.8 +/- 12.2 years) as a control group. Compared to a control group, the diabetic patients had a significantly higher mean t-PA antigen (5.15 +/- 3.02 vs 3.20 +/- 2.30 ng/ml) and PAl-1 antigen (35.89 +/- 18.59 vs 17.60 +/- 15.36 ng/ml) levels (p < 0.05). Plasma t-PA antigen level was not influenced by each treatment modality. There was a significant decrease of plasma PAl-1 antigen level after Metformin administration compared to that of before Metformin administration (39.74 +/- 19.39 vs 25.14 +/- 16.18 ng/ml) (p < 0.05), and the insulin-treated group showed a tendency for a decrease of plasma PAl-1 antigen levels after insulin administration but this did not reach statistical significance (29.93 +/- 15.37 vs 17.32 +/- 10.60 ng/ml). Sulfonylurea did not change both plasma t-PA and PAl-1 antigen levels. In conclusion, diabetic patients have high t-PA and PAl-1 antigen levels. Biguanide reduced plasma PAl-1 antigen levels, which might play some helpful role in the improvement of chronic complications in NIDDM.
authors.affiliation: Department of Internal Medicine, Soonchunhyang University College of Medicine, Chunan, Korea.
authors.forename: Y W
authors.initials: YW
authors.lastname: Cho
authors.forename: D H
authors.initials: DH
authors.lastname: Yang
authors.forename: D Y
authors.initials: DY
authors.lastname: Oh
authors.forename: S H
authors.initials: SH
authors.lastname: Baick
authors.forename: S K
authors.initials: SK
authors.lastname: Kim
authors.forename: S J
authors.initials: SJ
authors.lastname: Kim
authors.forename: S Y
authors.initials: SY
authors.lastname: Hong
mesh_terms: D000941:Antigens / Q000097:blood; D016022:Case-Control Studies; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000188:drug therapy; D003925:Diabetic Angiopathies / Q000517:prevention & control; D005260:Female; D005342:Fibrinolysis / Q000187:drug effects*; D005907:Gliclazide / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007328:Insulin / Q000494:pharmacology / Q000627:therapeutic use; D008297:Male; D008687:Metformin / Q000494:pharmacology* / Q000627:therapeutic use; D008875:Middle Aged; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood* / Q000276:immunology; D010959:Tissue Plasminogen Activator / Q000097:blood* / Q000276:immunology
chemical_list: D000941:Antigens; D007328:Insulin; D017395:Plasminogen Activator Inhibitor 1; D008687:Metformin; D010959:Tissue Plasminogen Activator; D005907:Gliclazide